A patent attack on three fronts

The Indian patent system has been known for its strict prosecution of patents in the pharmaceutical sector ever since the product patent regime came into force in 2005. Furthermore, several opportunities are provided to third parties to challenge patent applications and make use of multiple pre-grant oppositions, while post-grant attacks are the norm for important pharma product patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

China’s medtech shake-up forces rethink on pricing, IP and innovation

3 July 2026 A report warns that procurement reforms in Mainland China, alongside the rise of open robotics platforms, supply chain disruption and GLP-1 drugs, are challenging existing medtech business models.

Asia

‘Blatant imitation’: Indian court blocks copycat pharma branding

22 June 2026 The court granted Blue Cross Laboratories a permanent injunction after finding that a rival product’s mark and packaging closely mirrored its own.

Asia

Takeda’s China IP head: What pharma is still getting wrong

27 May 2026 China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.

More features

China’s medtech shake-up forces rethink on pricing, IP and innovation

LSD trade secrets suit over clinical trail info thrown out by judge

HGF expands European offering with pair of in-house hires

What’s at stake in Australia’s biggest pharma patent appeal in years?

Vinson & Elkins grows West Coast patent and trade secrets bench

Will Mounjaro and Zepbound get their first US generic rival?

Merck KGaA agrees $11.3bn deal in major life sciences expansion

Pfizer’s US Paxlovid patent fight turns on a single error

A patent attack on three fronts

More on this story

Editor's picks

Editor's picks

More features